Drugs / Adecatumumab
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT07219368 | Oct 2025 → Nov 2026 expected | — | Mirador Therapeutics, Inc. | Recruiting | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT07113522 | Jun 2025 → Apr 2027 expected | Crohn disease, ulcerative colitis | Mirador Therapeutics, Inc. | Recruiting | No outcome recorded |
| Phase 2 | NCT00866944 | Mar 2009 → Jul 2011 | metastasis from malignant tumor of colon | Amgen Research (Munich) GmbH | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Adecatumumab | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00866944 ↗ |
| Known as | MT-201 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07113522 ↗ |
| Action | Inhibit | “Epithelial cell adhesion molecule inhibitor” CHEMBL2108018 ↗ |
| Modality | Monoclonal antibody | — CHEMBL2108018 ↗ |
| Route | Intravenous | “multiple intravenous doses of MT-201” NCT07113522 ↗ |
| Target | EPCAM | “Epithelial cell adhesion molecule inhibitor” CHEMBL2108018 ↗ |